CLARENDON HOUSE, HAMILTON, D0
Annual Meeting Results - Kiniksa Pharmaceuticals Shareholder Votes
Kiniksa Pharmaceuticals Enters Deed of Waiver with Baker Bros. Advisors
Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
Ross Moat Appointed Chief Operating Officer at Kiniksa Pharmaceuticals
Provides Corporate Update
Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Reg. FD
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Certification of Termination of Registration of a Class of Security
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence